EA202191228A1 - Липосомальная внутрибрюшинная химиотерапия с повышенной степенью эффективности - Google Patents

Липосомальная внутрибрюшинная химиотерапия с повышенной степенью эффективности

Info

Publication number
EA202191228A1
EA202191228A1 EA202191228A EA202191228A EA202191228A1 EA 202191228 A1 EA202191228 A1 EA 202191228A1 EA 202191228 A EA202191228 A EA 202191228A EA 202191228 A EA202191228 A EA 202191228A EA 202191228 A1 EA202191228 A1 EA 202191228A1
Authority
EA
Eurasian Patent Office
Prior art keywords
liposomal
efficacy
increased degree
intraperitoneal chemotherapy
treatment
Prior art date
Application number
EA202191228A
Other languages
English (en)
Inventor
Майкл Дж. Оэфелейн
Натараджан Венкатесан
Нитин К. Сварнакар
Тереза Б. Хонг
Гуру В. Бетагери
Рамачандран Тхирукоте
Лининг Жу Хатчинсон
Original Assignee
ТЕЗОРКС ФАРМА, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ТЕЗОРКС ФАРМА, ЭлЭлСи filed Critical ТЕЗОРКС ФАРМА, ЭлЭлСи
Publication of EA202191228A1 publication Critical patent/EA202191228A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Описанное в настоящем документе изобретение относится к лечению новообразований путем внутрибрюшинного введения липосомальных композиций химиотерапевтических лекарственных средств. Описаны способы введения каплями липосомальных композиций химиотерапевтических средств на основе таксана и платины в брюшную полость субъекта для лечения злокачественной опухоли яичников или первичной злокачественной опухоли брюшины.
EA202191228A 2018-11-02 2019-11-04 Липосомальная внутрибрюшинная химиотерапия с повышенной степенью эффективности EA202191228A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862755026P 2018-11-02 2018-11-02
PCT/US2019/059655 WO2020093044A1 (en) 2018-11-02 2019-11-04 Liposomal enhanced intra-peritoneal chemotherapy

Publications (1)

Publication Number Publication Date
EA202191228A1 true EA202191228A1 (ru) 2021-09-24

Family

ID=70462880

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202191228A EA202191228A1 (ru) 2018-11-02 2019-11-04 Липосомальная внутрибрюшинная химиотерапия с повышенной степенью эффективности

Country Status (16)

Country Link
US (1) US20220000777A1 (ru)
EP (1) EP3873456A4 (ru)
JP (1) JP2022506612A (ru)
KR (1) KR20210113588A (ru)
CN (1) CN113453667A (ru)
AU (1) AU2019372441A1 (ru)
BR (1) BR112021009940A8 (ru)
CA (1) CA3118530A1 (ru)
CL (1) CL2021001147A1 (ru)
EA (1) EA202191228A1 (ru)
IL (1) IL282860A (ru)
MX (1) MX2021005110A (ru)
PE (1) PE20211468A1 (ru)
PH (1) PH12021551004A1 (ru)
SG (1) SG11202104580PA (ru)
WO (1) WO2020093044A1 (ru)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4128173A (en) * 1975-10-28 1978-12-05 Harrison Lazarus Peritoneal fluid treatment apparatus, package and method
WO1994026253A1 (en) * 1993-05-19 1994-11-24 The Liposome Company, Inc. Liposome having a multicomponent bilayer which contains a bioactive agent as an integral component of the bilayer
WO1996015774A1 (en) * 1994-11-18 1996-05-30 Aphios Corporation Methods and apparatus for making liposomes containing hydrophobic drugs
CA2524478A1 (en) * 2003-05-02 2004-11-18 Aronex Pharmaceuticals, Inc. Lipid platinum complexes and methods of use thereof
MX2007004955A (es) * 2004-11-08 2007-06-14 Transave Inc Metodo de tratar cancer con formulaciones de compeusto de platino a base de lipido administradas intraperitonealmente.
WO2007056264A2 (en) * 2005-11-08 2007-05-18 Transave, Inc. Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US9107824B2 (en) * 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
WO2009059449A1 (en) * 2007-11-05 2009-05-14 Celsion Corporation Novel thermosensitive liposomes containing therapeutic agents
CA2842306A1 (en) * 2011-07-19 2013-01-24 Stc.Unm Intraperitoneally-administered nanocarriers that release their therapeutic load based on the inflammatory environment of cancers
CN104582732A (zh) * 2012-06-15 2015-04-29 布里格姆及妇女医院股份有限公司 治疗癌症的组合物及其制造方法
US10010481B2 (en) * 2014-07-02 2018-07-03 Paolo Gobbi Frattini S.R.L. Flexible package with a sealed sterile chamber for the reconsitution and administration of fluid medicinal or nutritional substances instillable into the body of a patient
EP3256110A4 (en) * 2015-02-13 2018-11-21 Op Nano Co., Ltd. Compositions and methods of tumor treatment utilizing nanoparticles
CA2976912A1 (en) * 2015-02-17 2016-08-25 Mallinckrodt Llc Modified docetaxel liposome formulations and uses thereof
AU2017205337B2 (en) * 2016-01-07 2022-09-08 Tesorx Pharma, Llc Formulations for treating bladder cancer

Also Published As

Publication number Publication date
SG11202104580PA (en) 2021-05-28
KR20210113588A (ko) 2021-09-16
US20220000777A1 (en) 2022-01-06
EP3873456A4 (en) 2022-07-27
CN113453667A (zh) 2021-09-28
CL2021001147A1 (es) 2021-11-26
CA3118530A1 (en) 2020-05-07
MX2021005110A (es) 2021-08-24
AU2019372441A1 (en) 2021-06-10
EP3873456A1 (en) 2021-09-08
BR112021009940A2 (pt) 2021-08-17
WO2020093044A1 (en) 2020-05-07
JP2022506612A (ja) 2022-01-17
PE20211468A1 (es) 2021-08-05
IL282860A (en) 2021-06-30
PH12021551004A1 (en) 2021-10-04
BR112021009940A8 (pt) 2023-03-21

Similar Documents

Publication Publication Date Title
CY1121573T1 (el) Συζευγμα αντισωματος anti-her2-φαρμακου
EA201890125A1 (ru) Новые гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их
CY1124242T1 (el) Συνδυαστικη θεραπεια καρκινου
CY1125047T1 (el) Διεργασιες για την παρασκευη ενωσεων τυπου οξαθειαζινης
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
CY1124529T1 (el) Ενωσεις λευκοχρυσου λειτουργικοποιημενες με μονομηλεινιμιδιο για θεραπεια καρκινου
EA201790086A1 (ru) Комбинации для лечения раковых заболеваний
EA201692091A1 (ru) Хиноксалиновые соединения и их применение
EA201792287A1 (ru) Способы лечения рака
EA202192905A1 (ru) Соединения, содержащие n-метил-2-пиридон, и фармацевтически приемлемые соли
EA201892834A1 (ru) Комбинированная химиотерапия
EA202191114A1 (ru) Производные пиридинилсульфонамида, фармацевтические композиции и их применение
NZ722345A (en) Pyrazolone compounds and uses thereof
EA201990567A1 (ru) Комбинированная терапия с ингибиторами глутаминазы
CY1122077T1 (el) Νεα δακτυλιωμενα φαινοξυακεταμιδια
EA201792425A1 (ru) Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз
EA201690230A1 (ru) Соединения триазолона и их применения
EA201991196A1 (ru) Претерпевшие самосборку диблок-сополимеры, состоящие из pegmema и несущих лекарственное средство полимерных сегментов
BR112017021194A2 (pt) compostos espirocíclicos
EA201990370A1 (ru) Терапия рака, связанная с crebbp
CY1122357T1 (el) Αντικαρκινικος συνδυασμος που περιλαμβανει καμπαζιταξελη και σισπλατινη
EA201990311A1 (ru) АНТИМЕТАСТАТИЧЕСКИЕ 2H-СЕЛЕНОФЕН[3,2-h]ХРОМЕНЫ, СИНТЕЗ И СПОСОБЫ ПРИМЕНЕНИЯ
CY1124543T1 (el) Τμηματα χορηγησης δοσολογησης ανοσοθεραπευτικων που περιλαμβανουν πομαλιδομιδιο και αντισωμα anti-cs1 για αγωγη καρκινου
EA202090978A1 (ru) Новые макроциклические производные, способ их получения и содержащие их фармацевтические композиции
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение